Author:
Bourke Liam,Turner Rebecca,Greasley Rosa,Sutton Eileen,Steed Liz,Smith Dianna,Brown Janet,Kelly Ben,Hulme Claire,Greenfield Diana,Persad Raj,Farrin Amanda,Hewison Jenny,Rosario Derek J.,
Funder
National Institute for Health Research
Publisher
Public Library of Science (PLoS)
Reference33 articles.
1. CRUK Prostate cancer statistics (2014). Accessed 10/02/17 at http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer
2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer;A Heidenreich;European Urology,2014
3. NICE (2014) Prostate cancer: diagnosis and treatment. NICE clinical guideline 175.
4. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial;ND James;Lancet,2016
5. Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?;L Bourke;British Journal of Cancer,2013